- ADORING 1 and ADORING 2 met their primary efficacy endpoints and all secondary endpoints - - ADORING 1 and ADORING 2 data were included in the sNDA filing for VTAMA cream, 1% in atopic dermatitis
Dermavant Sciences: Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Dermavant Sciences: Dermavant Announces Positive Data from the ADORING Phase 3 Development Program in Atopic Dermatitis with VTAMA (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Dermavant Sciences: Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head and Neck Region in Adults finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.